Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia

Participants (N = 233) were mostly women (66%), a mean of 52.8 years old, who had CD for a mean of 51.9 months. Of those, 39% were toxin-naïve. IncobotulinumtoxinA significantly improved TWSTRS-Total scores from baseline to Week 4 compared to placebo (placebo = −2.2; 120 U = −9.9, and 240 U = −10.9; 240 U vs. placebo p < 0.001 and 120 U vs. placebo p < 0.001). This effect persisted through to the end of the study. The most frequently reported AEs in the incobotulinumtoxinA groups were dysphagia, neck pain, and muscular weakness which were generally mild. Interpretation: IncobotulinumtoxinA (at doses of 120 U or 240 U) is a safe and effective treatment for CD in previously-treated as well as toxin-naïve subjects.